Table 1 Baseline patients characteristics
Characteristic | N (%) |
|---|---|
Age | |
< 75 years | 319 (82.0) |
≥ 75 years | 70 (18.0) |
Median (range) age, years 65 (34–85) | |
Gender | |
Male | 291 (74.8) |
Female | 98 (25.2) |
ECOG performance status | |
0 | 176 (47.1) |
1 | 174 (46.5) |
2 | 24 (6.4) |
NA | 15 |
IMDC prognostic group | |
Favourable | 62 (20.2) |
Intermediate | 212 (69.1) |
Poor | 33 (10.7) |
NA | 82 |
Nephrectomy | |
Yes | 369 (94.9) |
No | 20 (5.1) |
Histology | |
Clear-cell | 356 (91.5) |
Non-clear-cell | 26 (6.7) |
Undifferentiated/Unknown | 7 (1.8) |
Metastasis site | |
Lung | 286 (73.5) |
Lymph node | 238 (69.2) |
Bone | 193 (49.6) |
Liver | 128 (32.9) |
Brain | 32 (8.2) |
Number of prior systemic therapies | |
1 | 80 (20.7) |
2 | 137 (35.4) |
≥ 3 | 170 (43.9) |
First-line therapy | |
Sunitinib | 261 (67.4) |
Pazopanib | 80 (20.7) |
Other | 46 (11.9) |
Prior everolimus | |
Yes | 163 (42.1) |
No | 224 (57.9) |